{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:56:03Z","timestamp":1794434163525,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024619","name":"Ohio Attorney General's Office","doi-asserted-by":"publisher","award":["10010656GR"],"award-info":[{"award-number":["10010656GR"]}],"id":[{"id":"10.13039\/100024619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.drugalcdep.2025.112710","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:44:01Z","timestamp":1747223041000},"page":"112710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Enhanced pharmacokinetic and pharmacodynamic effects of combining p-fluorofentanyl and fentanyl"],"prefix":"10.1016","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9508-260X","authenticated-orcid":false,"given":"Jeremy R.","family":"Canfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla K.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0349-5072","authenticated-orcid":false,"given":"Jon E.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112710_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.pa.28.040188.002241","article-title":"The opioid system and temperature regulation","volume":"28","author":"Adler","year":"1988","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib3","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67523","article-title":"Dual mechanisms of opioid-induced respiratory depression in the inspiratory rhythm-generating network","volume":"10","author":"Baertsch","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib4","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s00213-021-05981-x","article-title":"Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats","volume":"238","author":"Bergh","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.04.002","article-title":"Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats","volume":"158","author":"Bergh","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.15585\/mmwr.mm7139a3","article-title":"Notes from the field: overdose deaths involving para-fluorofentanyl \u2014 United States, July 2020\u2013June 2021","volume":"71","author":"Bitting","year":"2022","journal-title":"Mmwr. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib7","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1021\/jm9810194","article-title":"Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance","volume":"41","author":"Bois","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/add.16527","article-title":"Para-fluorofentanyl: coincidence or intentional?","volume":"119","author":"Canfield","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/dta.3636","article-title":"Influence of carbon side chain length on the in vivo pharmacokinetic and pharmacodynamic characteristics of illicitly manufactured fentanyls","volume":"16","author":"Canfield","year":"2023","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00204-024-03887-z","article-title":"In vivo pharmacokinetic, pharmacodynamic and brain concentration comparison of fentanyl and para-fluorofentanyl in rats","volume":"99","author":"Canfield","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib11","unstructured":"Centers for Disease Control and Prevention, 2024a. U.S. overdose deaths decrease in 2023, first time since 2018. \u3008https:\/\/blogs.cdc.gov\/nchs\/2024\/05\/15\/7623\/\u3009 (Accessed February 21, 2025)"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib12","unstructured":"Centers for Disease Control and Prevention, 2024b. Polysubstance Overdose. \u3008https:\/\/www.cdc.gov\/overdose-prevention\/about\/polysubstance-overdose.html\u3009 (Accessed February 21, 2025)."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003088-200140080-00001","article-title":"Measures of exposure versus measures of rate and extent of absorption","volume":"40","author":"Chen","year":"2001","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/pharmaceutics12090846","article-title":"Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice","volume":"12","author":"Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1213\/ane.0b013e31818e0bd1","article-title":"Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: Pharmacokinetics and pharmacodynamics in Sprague-Dawley Rats","volume":"108","author":"Elkiweri","year":"2009","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tins.2015.01.002","article-title":"Understanding opioid reward","volume":"38","author":"Fields","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0022-3565(25)33602-5","article-title":"Subclasses of opioids based on body temperature change in rats: acute subcutaneous administration","volume":"225","author":"Geller","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-019-0625-0","article-title":"The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib20","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2019.10796","article-title":"Organic anion transporting polypeptide 1A2 mediates fentanyl uptake in cultured cells","author":"Huo","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau1184","article-title":"Changing Dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1373\/clinchem.2017.281626","article-title":"The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union","volume":"65","author":"Jannetto","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8069-9-45","article-title":"Sex differences in opioid analgesia and addiction: Interactions among opioid receptors and estrogen receptors","volume":"9","author":"Lee","year":"2013","journal-title":"Mol. Pain."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib24","unstructured":"Michigan Department of Health and Human Services, 2022. Emerging trend: Para-fluorofentanyl (pFF) increase in Michigan. \u3008https:\/\/www.michigan.gov\/opioids\/-\/media\/Project\/Websites\/opioids\/documents\/Para-fluorofentanyl_Edited.pdf\u3009 (Accessed February 21, 2025)"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib25","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.17496","article-title":"Illicitly manufactured fentanyl entering the United States","author":"Pergolizzi","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0361-9230(85)90192-3","article-title":"Sex and strain differences in morphine-induced temperature effects in WKYs and SHRs","author":"Quock","year":"1985","journal-title":"Brain Res. Bull. 14"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jat\/bkab025","article-title":"Concentrations of para-fluorofuranylfentanyl in paired central and peripheral blood collected during postmortem death investigations","volume":"46","author":"Rodriguez Salas","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib28","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1152\/jn.00113.2022","article-title":"Fentanyl effects on respiratory neuron activity in the dorsolateral pons","volume":"128","author":"Saunders","year":"2022","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.pain.2003.08.008","article-title":"Pharmacogenetic analysis of sex differences in opioid antinociception in rats","volume":"106","author":"Terner","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib30","unstructured":"The New York Times, 2024. How Mexican cartels test fentanyl on vulnerable people and animals. \u3008https:\/\/www.nytimes.com\/2024\/12\/26\/world\/americas\/mexican-cartels-test-fentanyl.html?unlocked_article_code=\u20091.kU4.rzUV.1rWlxmOayPio&smid=em-share\u3009 (Accessed February 21, 2025)"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib31","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1021\/acs.jcim.1c00362","article-title":"Data-driven ensemble docking to map molecular interactions of steroid analogs with hepatic organic anion transporting polypeptides","volume":"61","author":"Tuerkova","year":"2021","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib32","article-title":"National Forensic Laboratory Information System: NIFLIS-Drug 2022 annual report. U.S. Department of Justice","author":"U.S. Drug Enforcement Administration, Diversion Control Division","year":"2023","journal-title":"U. S. Drug Enforc. Adm., Springf., VA"},{"key":"10.1016\/j.drugalcdep.2025.112710_bib33","article-title":"Fentanyl analog structure-activity relationships demonstrate determinants of diverging potencies for antinociception and respiratory depression","volume":"226","author":"Varshneya","year":"2023","journal-title":"Pharmacol. Biochem. Beha."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acs.molpharmaceut.8b01214","article-title":"Halogen substitution influences ketamine metabolism by cytochrome P450 2B6: In vitro and computational approaches","volume":"16","author":"Wang","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00238","article-title":"Metabolic pathways and potencies of new fentanyl analogs","volume":"10","author":"Wilde","year":"2019","journal-title":"Front. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/08958378.2017.1282065","article-title":"Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone","volume":"29","author":"Wong","year":"2017","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/toxsci\/kfy093","article-title":"P-glycoprotein on blood-brain barrier plays a vital role in fentanyl brain exposure and respiratory toxicity in rats","volume":"164","author":"Yu","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.drugalcdep.2025.112710_bib38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin. Pharm."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:00:55Z","timestamp":1774530055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625001632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"alternative-id":["S0376871625001632"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112710","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced pharmacokinetic and pharmacodynamic effects of combining p-fluorofentanyl and fentanyl","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112710"}}